SOURCE: IO News Wire

IO News Wire

March 08, 2010 07:15 ET

(OTC: HIRU) Posts Tremendous Gains in 2009

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY--(Marketwire - March 8, 2010) -  Hiru Corporation (PINKSHEETS: HIRU) announced earlier this month that their subsidiary Jiangxi RongYu Pharmaceuticals, posted over $4 million in gross profits on $24 million in gross revenues.

Jiangxi RongYu Pharmaceutical Group Co., Ltd is a leader in the Chinese naturopathic medicine market. Naturopathic medicine is a branch of medicine in which a variety of natural medicines and treatments are used to heal illness. China currently holds over 10% of this market, approximately $8 billion, with an expected doubling of the market in the next 5 years.

Jiangxi RongYu is in a position to capitalize on the growth with recent announcements that several of its products have been added to China's National Essential Drugs List. All medicines placed on this list must be available to doctors and in stock in pharmacies and county hospitals throughout the country of China.

For more information, please visit www.minamargroup.net/our_clients.html

Other active stocks are Eli Lilly & Co (NYSE: LLY) American Oriental Bioengineering (NYSE: AOB) and Dana Resources (PINKSHEETS: DANR)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information